A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial
Primary result · ASES scoreResult — go to the resultβ 0.44Authors' conclusion
This app-based self-management intervention was not superior to usual care regarding self-efficacy improvement.
Study context
- Population
- Patients with RA (mean disease duration 12 years, age 58, 68% female, DAS28-CRP 2.4)
- Participants
- 122 patients
- Comparison
- App-based self-management intervention vs usual care
- Primary endpoint
- Improvement in Arthritis Self-Efficacy Scale (ASES)
- Follow-up
- 16 weeks
Methodological detailsmulticentre, 2:1:1 allocation
- Multicentre
- 2:1:1 allocation
Primary result
ASES score
β
0.44
P = 0.87
As reported in the abstract
Secondary outcomes
| Outcome | β (95% CI) |
|---|---|
| Pain Catastrophizing Scale (PCS), non-inferiorityIntervention vs Usual care · favouring the intervention · Non-inferiority established | −0.95 (−3.30, +1.40) |
Other predefined outcomes (physical activity, sleep quality, Rheumatoid Arthritis Impact of Disease (RAID))
- Did not differ
App retention · 16 weeks
- App retention steadily declined
- 43%
App users with ≥1 episode of clinically relevant RAID worsening · 16 weeks
- App users reporting ≥1 episode of clinically relevant worsening
- 35%
- RAID remained stable over time overall
Original publication
A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial. Rheumatology (Oxford). Published 22 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →